Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study

AIM OF THE STUDY: To optimize the long-term outcomes of patients with non-alcoholic fatty liver disease (NAFLD), long-term therapy is important to prevent cirrhosis and hepatocellular carcinoma. Pemafibrate, a novel selective peroxisome proliferator-activated receptor-α modulator, is a promising the...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinozaki, Satoshi, Tahara, Toshiyuki, Lefor, Alan Kawarai, Ogura, Masahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284174/
https://www.ncbi.nlm.nih.gov/pubmed/34295984
http://dx.doi.org/10.5114/ceh.2021.106864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284174/
https://www.ncbi.nlm.nih.gov/pubmed/34295984
http://dx.doi.org/10.5114/ceh.2021.106864

Ejemplares similares